Dupixent started 2023 the way it ended 2022: at the top. The severe asthma treatment had the largest impressions share of voice (SOV) among Rx and over-the-counter pharma brands in January, totaling ...
In the pharma TV ad race, Dupixent and Humira are trading the top spending spots—again. Sanofi and Regeneron’s asthma and eczema drug climbed back to No. 1 in May, while AbbVie’s blockbuster ...
The first half of the top monthly Rx and over-the-counter (OTC) pharma brands in May looks a lot like it did in April. The rankings are identical, actually. For the second consecutive month, Dupixent ...
Sanofi and Regeneron’s immunology blockbuster Dupixent had been on a mini streak as king of the pharma airwaves but was knocked off its perch in June by AbbVie’s competing drug Rinvoq. That’s ...
While non-response to Dupixent is uncommon, atopic dermatitis (AD) patients who are refractory lack safe and effective treatments according to REACH Market Research. NEWTON, Mass., July 26, 2023 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback